Navigating Policy Shifts at the FDA, USPTO, and NIH: Strategic & Legal Insights for Biotech Entrepreneurs
So You Want to Do Business with the Government
Unlock Strategic Insights for Biotechnology Innovators
Biotechnology entrepreneurs, this is your chance to gain critical knowledge to navigate the evolving intersection of federal policies and biotech innovation. Join WilmerHale Partners for a comprehensive discussion covering NIH grants, FDA reviews and timelines, USPTO policies, and intellectual property strategies.
Meet the Experts:
Barish Ozdamar: Renowned for his expertise in intellectual property disputes and IP portfolio development, Dr. Ozdamar brings deep insights into areas like gene therapy, CRISPR, vaccines, diagnostics, and more.
Barry J. Hurewitz: With his multidisciplinary experience in government transactions and regulation of technology, Mr. Hurewitz will guide you through key strategies in funding opportunities, compliance, and government rights in patents and data.
Why Attend?
Gain essential legal and strategic insights to adapt to shifting federal policies.
Discover innovative approaches to intellectual property, and regulatory navigation considering the shift in administration and leadership.
Participate in a dynamic Q&A session to address your specific challenges.
Enjoy light refreshments and networking opportunities with experts and peers.
About WilmerHale: With over 1,100 lawyers across 12 offices, WilmerHale is a leading international law firm at the forefront of government, technology, and business.